Peter Blume Jensen PhD, MD

Dr. Peter Blume-Jensen has extensive expertise in basic and translational cancer research, oncogenic signaling, targeted therapeutics drug discovery, and stratified clinical trial design. From 2001 to 2008 Peter was Department Head at Serono, US and later at Merck & Co, Inc. where he established novel, integrated oncology drug discovery programs linking therapeutics to patient responder populations and advanced a number of pre-clinical drug programs into the clinic.

Dr. Blume-Jensen has authored highly-cited articles, reviews, and book chapters in Personalized Molecular Oncology. His review ‘Oncogenic Kinase Signaling’ in Nature is a citation classic in ‘Clinical Medicine’, and his work on genetically engineered cancer and male infertility mouse models has been widely portrayed on CNN and other news channels.

His approaches for efficacy-predictive biomarkers have appeared on Nature Biotechnology’s ‘Hot patents’ watch-list and in numerous Editorial highlights for Personalized Oncology. Dr. Blume-Jensen obtained his M.D. from Copenhagen, Denmark, his Ph.D. from Dr. Carl-Henrik Heldin’s laboratory at the Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral studies in Dr. Tony Hunter’s laboratory at the Salk Institute, La Jolla, CA.